{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T05:53:23Z","timestamp":1719986003075},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,14]]},"DOI":"10.7759\/cureus.17957","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T11:19:16Z","timestamp":1631618356000},"source":"Crossref","is-referenced-by-count":1,"title":["Tofacitinib Treatment in Patients With Active COVID-19 Infection"],"prefix":"10.7759","author":[{"given":"Abdulmajeed  M","family":"Alajlan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lama R","family":"AlZamil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal M","family":"Aseri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10347","article-title":"Prevalence of alopecia areata in Saudi Arabia: cross-sectional descriptive study","volume":"12","author":"Al-Ajlan A","year":"2020","unstructured":"Al-Ajlan A, Alqahtani ME, Alsuwaidan S, Alsalhi A. Prevalence of alopecia areata in Saudi Arabia: cross-sectional descriptive study. Cureus. 2020, 12:e10347. 10.7759\/cureus.10347","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14746","article-title":"Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic","volume":"34","author":"A\u015fk\u0131n \u00d6","year":"2021","unstructured":"A\u015fk\u0131n \u00d6, \u00d6zkoca D, Uzun\u00e7akmak TK, Serdaro\u011flu S. Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic. Dermatol Ther. 2021, 34:e14746. 10.1111\/dth.14746","journal-title":"Dermatol Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea JJ","year":"2013","unstructured":"O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013, 72:ii111-5. 10.1136\/annrheumdis-2012-202576","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0040-7","article-title":"The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders","volume":"27","author":"Furumoto Y","year":"2013","unstructured":"Furumoto Y, Gadina M. The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs. 2013, 27:431-8. 10.1007\/s40259-013-0040-7","journal-title":"BioDrugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00931-6","article-title":"JAK inhibitors: what is new?","volume":"22","author":"Reddy V","year":"2020","unstructured":"Reddy V, Cohen S. JAK inhibitors: what is new?. Curr Rheumatol Rep. 2020, 22:50. 10.1007\/s11926-020-00931-6","journal-title":"Curr Rheumatol Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15937","article-title":"Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis","volume":"34","author":"Guo L","year":"2020","unstructured":"Guo L, Feng S, Sun B, Jiang X, Liu Y. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020, 34:192-201. 10.1111\/jdv.15937","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa093","article-title":"Case report of a SARS-CoV-2 infection in a patient with ulcerative colitis on tofacitinib","volume":"26","author":"Jacobs J","year":"2020","unstructured":"Jacobs J, Clark-Snustad K, Lee S. Case report of a SARS-CoV-2 infection in a patient with ulcerative colitis on tofacitinib. Inflamm Bowel Dis. 2020, 26:e64. 10.1093\/ibd\/izaa093","journal-title":"Inflamm Bowel Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa303","article-title":"Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD registry","volume":"27","author":"Agrawal M","year":"2021","unstructured":"Agrawal M, Brenner EJ, Zhang X, et al.. Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD registry. Inflamm Bowel Dis. 2021, 27:585-9. 10.1093\/ibd\/izaa303","journal-title":"Inflamm Bowel Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05730-z","article-title":"JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis","volume":"21","author":"Walz L","year":"2021","unstructured":"Walz L, Cohen AJ, Rebaza AP, Vanchieri J, Slade MD, Dela Cruz CS, Sharma L. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. BMC Infect Dis. 2021, 21:47. 10.1186\/s12879-020-05730-z","journal-title":"BMC Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000508247","article-title":"JAK inhibition as a new treatment strategy for patients with COVID-19","volume":"181","author":"Seif F","year":"2020","unstructured":"Seif F, Aazami H, Khoshmirsafa M, Kamali M, Mohsenzadegan M, Pornour M, Mansouri D. JAK inhibition as a new treatment strategy for patients with COVID-19. Int Arch Allergy Immunol. 2020, 181:467-75. 10.1159\/000508247","journal-title":"Int Arch Allergy Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/68211-tofacitinib-treatment-in-patients-with-active-covid-19-infection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:56Z","timestamp":1707507236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/68211-tofacitinib-treatment-in-patients-with-active-covid-19-infection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.17957","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,14]]}}}